Heron Therapeutics, Inc. (HRTX)
HRTXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.3731
+0.0025 (+0.67%) today
Regular session, Nov 10, 3:24 PM ET
- Market cap
- $70.83m
- P/E
- –
- EPS, last 4 quarters
- $-0.1200
- Dividend yield
- –
- Day range
- $0.3400 to $0.4100
- 52-week range
- $0.2610 to $1.58
- Average volume
- 4.71m
- Previous close
- $0.3706
Earnings
next estimate $-0.0300Next report
Dec 2025
+33.3%
Mar 2026
-33.3%
Jun 2026
-50.0%
Sep 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $38.21m | $40.59m | $34.71m | $37.67m |
| Gross profit | $26.30m | $29.47m | $24.07m | $26.09m |
| Operating income | -$4.09m | $38.0k | -$4.76m | -$2.04m |
| Net income | -$17.50m | -$2.95m | -$8.11m | -$5.49m |
Last four quarters: revenue $151.18m, margin -22.5%, free cash flow –
News
8 latest- CRMD to Acquire HRTX Assets for $223M Upfront to Expand PortfolioZacks · 7 hours ago
- Heron Therapeutics, Inc. Reports Q3 2026 Financial Results and Proposed Asset Sale to CorMedixFintel · 1 day ago
- Heron Therapeutics, Inc. to Sell Substantially All Assets to CorMedix Inc. for $145.0 million in Cash and 14,583,333 SharesFintel · 1 day ago
- Heron Therapeutics Reports Q3 Revenue Of $35.3 Mln; Agrees To Sell Assets To CorMedix RTTNews · 1 day ago
- CorMedix, Heron Strike $223 Mln Upfront Asset Deal; Closing Expected In 2027; Stock Up RTTNews · 1 day ago
- Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue EstimatesZacks · 1 day ago
- CorMedix To Acquire Heron's Commercial Drug Portfolio In $223 Mln Deal; Stock Up RTTNews · 1 day ago
- Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue EstimatesZacks · 5 days ago
The company
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- herontx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.